Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness
Anti-SARS-CoV2 vaccination coverage was similar between SLE patients and the general population in Sweden. Even though the incidence of post-vaccination COVID-19 hospitalization was very low, vaccine effectiveness was diminished in SLE patients compared to the general population and lowest in those treated with immunosuppressants.
Authors
- Elizabeth V. Arkema (ORCID: https://orcid.org/0000-0002-3677-9736)
- Elisabet Svenungsson (ORCID: https://orcid.org/0000-0003-3396-3244)
- Arthur Mageau (ORCID: https://orcid.org/0000-0002-2995-767X)
- Julia F. Simard (ORCID: https://orcid.org/0000-0001-5735-9856)
Institutions
- Karolinska University Hospital (SE)
- Inserm (FR)
- Université Paris Cité (FR)
- Karolinska Institutet (SE)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Stanford University (US)
Publication Details
- Journal
- Lupus
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1177/09612033241273052
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Fondation pour la Recherche Médicale